Climb Bio (CLYM) Interest Coverage Ratio (2020 - 2026)
Climb Bio's (CLYM) quarterly Interest Coverage Ratio came in at 0.47 in Q1 2026, up 98.91% YoY from 0.24 in Q1 2025, and up 71.43% on a QoQ basis from 1.65 in Q4 2025.
Climb Bio (CLYM) Interest Coverage Ratio (2020 - 2026) Analysis & Trends
Climb Bio (CLYM) has 7 years of Interest Coverage Ratio data on file, last reported at 0.47 in Q1 2026.
- Quarterly Interest Coverage Ratio rose 98.91% year-over-year to 0.47 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 1.86 (up 99.03% YoY) and the FY2025 annual result came in at 5.79, down 101.08% from the prior year.
- Interest Coverage Ratio grew to 0.47 in Q1 2026, from 1.65 in the prior quarter.
- In the past five years, Interest Coverage Ratio ranged from a high of 0.25 in Q4 2023 to a low of 296.58 in Q2 2025.
- A 5-year average of 26.76 and a median of 3.48 in 2022 frame the typical range for Interest Coverage Ratio.
- Annual changes were most pronounced in 2024 — Interest Coverage Ratio sank 17671.17% — and 2026, when it surged 98.91%.
- Tracing CLYM's Interest Coverage Ratio over 5 years: stood at 1.68 in 2022, then surged by 85.35% to 0.25 in 2023, then slumped by 17671.17% to 43.64 in 2024, then surged by 96.23% to 1.65 in 2025, then jumped by 71.43% to 0.47 in 2026.
- The last three Interest Coverage Ratio figures came in at 0.47 (Q1 2026), 1.65 (Q4 2025), and 9.27 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Cover (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 2.84 |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 24.64 |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -0.19 |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 8.18 |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -0.01 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 0.61 |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 2.82 |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -0.08 |
| 10 | Climb Bio | 1.24 Bn | 1.24 Bn | - | -0.19 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -0.19 |
| Mar 31, 2026 | -0.47 |
| Dec 31, 2025 | -1.65 |
| Sep 30, 2025 | -9.27 |
| Jun 30, 2025 | -296.58 |
| Mar 31, 2025 | -43.10 |
| Dec 31, 2024 | -43.64 |
| Sep 30, 2024 | -12.52 |
| Jun 30, 2024 | -20.22 |
| Mar 31, 2024 | -2.80 |
| Dec 31, 2023 | -0.25 |
| Sep 30, 2023 | -3.80 |
| Jun 30, 2023 | -3.01 |
| Mar 31, 2023 | -9.61 |
| Dec 31, 2022 | -1.68 |
| Sep 30, 2022 | -2.04 |
| Jun 30, 2022 | -3.48 |
| Mar 31, 2022 | -0.82 |
| Dec 31, 2021 | -1.00 |
| Sep 30, 2021 | -0.22 |